Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, on X, adding the following:
“Results from a randomized phase 3 trial will be presented this Thursday at the ESMO Virtual Plenary – intriguing data for all breast oncologists!!”
Quoting Giampaolo Bianchini’s post:
“Join us at the next ESMO Virtual Plenary session!
- Is there a new PARPi option for HER2-neg gBRCA1/2mut MBC?
- Does a combination of PARPi and antiangiogenic drug (apatinib) improve efficacy?
- Are VEGFRi better than bevacizumab?”
Source: Elisa Agostinetto/X and Giampaolo Bianchini/X
